Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02560363
Other study ID # D6400C00003
Secondary ID 2015-002807-26
Status Withdrawn
Phase Phase 1
First received September 24, 2015
Last updated January 8, 2016
Start date November 2015
Est. completion date January 2016

Study information

Verified date January 2016
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

This is an open-label, randomized, cross over single oral dose study to compare the pharmacokinetics of different formulations of AZD9977 in Part A and the influence of food in Part B in healthy male subjects


Description:

This is an open-label, randomized, cross over single oral dose study to compare the pharmacokinetics of three different extended-release formulations and an immediate-release formulation (reference) of AZD9977 in Part A and the influence of food in Part B in healthy male subjects


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Provision of signed and dated, written informed consent prior to any study specific procedures.

- Healthy male subjects aged 18 to 50 years with suitable veins for cannulation or repeated venipuncture.

- Male subjects have to comply with the restrictions for sexual activity provided to them.

- Have a body mass index (BMI) between 18 and 32 kg/m2, inclusive, and weigh at least 50 kg.

- Subject judged likely to complete and agree to eat a specified high-fat, high-calorie standardized FDA breakfast.

- Able to understand, read and speak the English language.

Exclusion Criteria:

- History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.

- History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.

- Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.

- Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis results, as judged by the investigator.

- Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) antibody.

- Abnormal findings in vital signs, after 10 minutes resting in the supine position, defined as any of the following:

- Systolic blood pressure (SBP) < 90 mmHg or = 140 mmHg

- Diastolic blood pressure (DBP) < 50 mmHg or = 90 mmHg

- Pulse < 45 or > 90 bpm

- Any clinically important abnormalities in rhythm, conduction or morphology of the electrocardiogram (ECG) at screening or pre-dose, as considered by the investigator.

- Prolonged QTcF > 450 ms or family history of long QT syndrome.

- PR (PQ) interval shortening < 120 ms (PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular pre-excitation).

- PR (PQ) interval prolongation > 240 ms; intermittent second (history of Wenckebach block while asleep is not exclusive) or third degree atrioventricular (AV) block or AV dissociation.

- Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB) or intraventricular conduction delay (IVCD) with QRS > 110 ms. Subjects with QRS > 110 ms but < 115 ms are acceptable if there is no evidence of ventricular hypertrophy or pre-excitation.

- Serum potassium higher than 5.0 mmol/L at screening or admission to the study center (Day -1).

- Known or suspected history of drug abuse, as judged by the investigator.

- Current smokers or those who have smoked or used nicotine products within the 3 months prior to screening.

- History of alcohol abuse or excessive intake of alcohol as judged by the investigator.

- Positive screen for drugs of abuse, alcohol or cotinine at screening or admission to the study center.

- History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9977.

- Excessive intake of caffeine containing drinks or food (e.g., coffee, tea and chocolate) as judged by the investigator.

- Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to first dose of AZD9977.

- Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during 2 weeks prior to 1st dosing in Part A, or longer if the medication has a long half-life.

- Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.

- Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or 1 month after the last visit whichever is the longest.

- Subjects who have previously received AZD9977

- Involvement of any AstraZeneca, PAREXEL, or study site employee or their close relatives.

- Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.

- Subjects who are vegans, vegetarians or have medical dietary restrictions.

- Subjects who cannot communicate reliably with the investigator.

- Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
AZD9977 immediate release (IR) oral suspension
120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose
AZD9977 extended release (ER) capsules [fast]
120 mg (2 x 60mg capsules) single dose
AZD9977 extended release (ER) capsules [intermediate]
120 mg (2 x 60mg capsules) single dose
AZD9977 extended release (ER) capsules [slow]
120 mg (2 x 60mg capsules) single dose

Locations

Country Name City State
United Kingdom Research Site Harrow

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate and extent of absorption of the extended-release formulations in comparison with an immediate-release formulation of AZD9977 by assessment of Frel (AUC) Relative bioavailability (Frel [AUC]) by assessement of the ratio of AUC (Area under plasma concentration-time curve from time zero extrapolated to infinity) between the extended-release formulations in comparison with an immediate-release formulation of AZD9977 Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day No
Primary Rate and extent of absorption of the extended-release formulations in comparison with an immediate-release formulation of AZD9977 by assessment of Frel (AUC0-t) Relative bioavailability (Frel [AUC0-t]) by assessement of the ratio of AUC (Area under the plasma concentration-curve from time zero to time of last quantifiable concentration) between the extended-release formulations in comparison with an immediate-release formulation of AZD9977 Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day No
Primary Rate and extent of absorption of the extended-release formulations in comparison with an immediate-release formulation of AZD9977 by assessment of Frel (AUC0-24) Relative bioavailability (Frel [AUC0-24]) by assessement of the ratio of AUC (Area under the plasma concentration-time curve from time zero to 24 hours post-dose) between the extended-release formulations in comparison with an immediate-release formulation of AZD9977 Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day No
Primary Rate and extent of absorption of the extended-release formulations in comparison with an immediate-release formulation of AZD9977 by assessment of Frel (Cmax) Relative bioavailability (Frel [Cmax]) by assessement of the ratio of AUC (Observed maximum plasma concentration) between the extended-release formulations in comparison with an immediate-release formulation of AZD9977 Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day No
Primary Rate and extent of absorption of an extended-release formulation of AZD9977 under fasting condtions in comparision with fed condtions by assessment of Frel (AUC) Relative bioavailability (Frel [AUC]) by assessement of the ratio of AUC (Area under plasma concentration-time curve from time zero extrapolated to infinity) after dosing of an extended-release formulation under fed and fasting conditions Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day No
Primary Rate and extent of absorption of an extended-release formulation of AZD9977 under fasting condtions in comparision with fed condtions by assessment of Frel(AUC0-t) Relative bioavailability (Frel [AUC0-t]) by assessement of the ratio of AUC (Area under the plasma concentration-curve from time zero to time of last quantifiable concentration) after dosing of an extended-release formulation under fed and fasting conditions Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day No
Primary Rate and extent of absorption of an extended-release formulation of AZD9977 under fasting condtions in comparision with fed condtions by assessment of Frel(AUC0-24) Relative bioavailability (Frel [AUC0-24]) by assessement of the ratio of AUC (Area under the plasma concentration-time curve from time zero to 24 hours post-dose) after dosing of an extended-release formulation under fed and fasting conditions Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day No
Primary Rate and extent of absorption of an extended-release formulation of AZD9977 under fasting condtions in comparision with fed condtions by assessment of Frel(Cmax) Relative bioavailability (Frel[Cmax]) by assessement of the ratio of AUC (Area under the plasma concentration-time curve from time zero to 24 hours post-dose) after dosing of an extended-release formulation under fed and fasting conditions Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 28, 32, 36 and 48 hours post-dose on each dosing day No
Secondary Safety and tolerabilty of AZD9977 by assessment of the number of adverse events and the number of subjects with adverse events To assess the safety and tolerability of single doses of AZD9977 From screening to post-study visit, up to 10 weeks Yes
Secondary Safety and tolerabilty of AZD9977 by assessment of cardiac telemetry To assess the safety and tolerability of single doses of AZD9977 On Day -1 and pre-dose until 24 hours post dose on Day 1 Yes
Secondary Safety and tolerabilty of AZD9977 by assessment of blood pressure To assess the safety and tolerability of single doses of AZD9977 From screening to post-study visit, up to 10 weeks Yes
Secondary Safety and tolerabilty of AZD9977 by assessment of pulse To assess the safety and tolerability of single doses of AZD9977 From screening to post-study visit, up to 10 weeks Yes
Secondary Safety and tolerability of AZD9977 by assessment of electrocardiogram To assess the safety and tolerability of single doses of AZD9977 From screening to post-study visit, up to 10 weeks Yes
Secondary Safety and tolerability of AZD9977 by assessment of physical examination This is a composite of the general appearance, skin, cardiovascular, respiratory, abdomen, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, musculoskeletal and neurological systems. From screening to post-study visit, up to 10 weeks Yes
Secondary Safety and tolerability of AZD9977 by assessment of safety laboratory tests This is a composite of clinical chemistry, hematology and urinalysis From screening to post-study visit, up to 10 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT04092725 - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Phase 1
Completed NCT04181008 - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers Early Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT04406415 - Oral Nafamostat in Healthy Volunteers Phase 1
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Completed NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid Phase 1
Completed NCT01976078 - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents N/A
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01682408 - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability Phase 1
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01260025 - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1
Completed NCT00730145 - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis Phase 1
Completed NCT00983242 - Drug-Drug Interaction Between Colchicine and Verapamil ER Phase 1
Completed NCT00856570 - A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects Phase 1
Completed NCT01055964 - a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients Phase 3
Completed NCT01276119 - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males Phase 1
Completed NCT00746499 - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. Phase 1